Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06070675
Other study ID # BUN B3002023000056
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date January 1, 2026

Study information

Verified date May 2024
Source Universiteit Antwerpen
Contact Lola Bladt, MSc
Phone 497848014
Email lola.bladt@uantwerpen.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare an automated bladder diary (autoBD) to a paper bladder diary (pBD) on their level of agreement, patient compliance and satisfaction. It is a mixed methods, randomized 2x2 crossover trial. Pediatric patients (6 to 12 years) presenting to the clinic and identified as requiring a bladder diary will be recruited. Participants will be randomized either to group 1, where they complete the paper bladder diary (pBD) and then the automated bladder diary (autoBD), or to group 2, where they complete the autoBD and then the pBD. Both diaries are kept for at least 2 consecutive days with a wash-out period of 2 to 6 days between the two diaries. Mean differences and the level of agreement between the pBD and autoBD will be analysed using Bland Altman plots for key diary parameters. After completion of each diary format, participants will complete a short online survey regarding compliance, satisfaction and their preference, if any. Finally, a selection of participants and their parents will be invited for an open-ended interview. The participating healthcare professionals will be asked to score each pBD and autoBD on patient compliance when processing the diary. Furthermore, surveys and open-ended interviews will be conducted to assess their overall satisfaction of each diary type and their preference, if any.


Description:

For some time now, patient compliance with paper bladder diaries is being questioned. Paper bladder diaries are often incomplete, unreliable and/or of low quality. Multiple electronic bladder diaries have been developed to overcome some of the limitations associated with paper bladder diaries. However, based on several comparison studies between paper and electronic bladder diaries, it is not clear whether an electronic format alone is truly superior to the paper format. The investigators want to introduce and evaluate the feasibility of a new type of bladder diary: an automated bladder diary. In contrast to an electronic diary, an automated diary automatically registers voiding data using a connected measuring device. An electronic diary simply eliminates the use of paper, but the patient still needs to measure the voided volumes with a urinary container and manually enter them in the electronic diary. The investigators believe an automated diary may lead to improved patient compliance by reducing the required efforts from the patient and instead provide guidance and prompts.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date January 1, 2026
Est. primary completion date September 1, 2025
Accepts healthy volunteers No
Gender All
Age group 6 Years to 12 Years
Eligibility Inclusion Criteria: - Pediatric patients presenting to the clinic and identified as requiring a bladder diary - Age: 6 to 12 years - Sex: male or female - Child and/or parent own and are able to operate a smartphone and/or tablet Exclusion Criteria: - Change in urologic treatment during the data collection period - Inability to hold the Diary Pod while urinating - Inability to speak, read and write Dutch

Study Design


Intervention

Device:
Minze Diary Pod
The automated bladder diary utilized in this study consists of the Minze Diary Pod and Minze Flow app. The Diary Pod is a capacitance-based measuring device, that automatically registers voided volumes and time of void. The Diary Pod connects via Bluetooth to the Minze Flow app to request additional information from the patient, such as urge, drinks and leakages.
Other:
Paper bladder diary
The paper bladder diary utilized in this study is a paper timetable that has the patient enter (in the columns of the timetable) drinks in ml, urinations in ml (using a measuring cup) and leakage episodes for the nearest hours (rows of the timetable).

Locations

Country Name City State
Belgium Privé praktijk dr. Katrien Klockaerts Aalst Oost-Vlaanderen
Belgium ZNA Koningin Paola Kinderziekenhuis Antwerpen
Belgium Imelda Ziekenhuis Bonheiden Antwerp
Belgium UZA Edegem Antwerpen
Belgium AZ Voorkempen Malle Antwerpen

Sponsors (1)

Lead Sponsor Collaborator
Universiteit Antwerpen

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Level of agreement average daytime volume (ml) What are the mean differences and the limits of agreement between the pBD and autoBD for average daytime volume (ml). Through study completion, an average of 1.5 year
Secondary Level of agreement maximum voided volume (ml) What are the mean differences and the limits of agreement between the pBD and autoBD for maximum voided volume (ml). Through study completion, an average of 1.5 year
Secondary Level of agreement 24h voided volume (ml) What are the mean differences and the limits of agreement between the pBD and autoBD for 24h voided volume (ml). Through study completion, an average of 1.5 year
Secondary Level of agreement nighttime voided volume (ml) What are the mean differences and the limits of agreement between the pBD and autoBD for nighttime voided volume (ml). Through study completion, an average of 1.5 year
Secondary Level of agreement average daytime volume versus age expected bladder capacity (%) What are the mean differences and the limits of agreement between the pBD and autoBD for average daytime volume versus age expected bladder capacity (%). Through study completion, an average of 1.5 year
Secondary Level of agreement maximum voided volume versus age expected bladder capacity (%) What are the mean differences and the limits of agreement between the pBD and autoBD for maximum voided volume versus age expected bladder capacity (%). Through study completion, an average of 1.5 year
Secondary Level of agreement nighttime voided volume versus age expected bladder capacity (%) What are the mean differences and the limits of agreement between the pBD and autoBD for nighttime voided volume versus age expected bladder capacity (%). Through study completion, an average of 1.5 year
Secondary Level of agreement nighttime voided volume versus 24h voided volume (%) What are the mean differences and the limits of agreement between the pBD and autoBD for nighttime voided volume versus 24h voided volume (%). Through study completion, an average of 1.5 year
Secondary Level of agreement nighttime voided volume versus daytime voiding frequency What are the mean differences and the limits of agreement between the pBD and autoBD for nighttime voided volume versus daytime voiding frequency. Through study completion, an average of 1.5 year
Secondary Level of agreement nighttime voided volume versus nighttime voiding frequency What are the mean differences and the limits of agreement between the pBD and autoBD for nighttime voided volume versus nighttime voiding frequency. Through study completion, an average of 1.5 year
Secondary Patient compliance reported by patient Subjective compliance will be assessed using topics such as completion, reliability, time to data entry, measuring accuracy, child involvement, child's and parents' motivation and interference with daily life. Through study completion, an average of 1.5 year
Secondary Patient compliance reported by healthcare provided Subjective compliance will be assessed using topics such as completion, measuring accuracy, quality, reliability and clinical usefulness Through study completion, an average of 1.5 year
Secondary Patient satisfaction Patient satisfaction will be assessed on usability, ergonomics, and diary preference. Through study completion, an average of 1.5 year
Secondary Healthcare professional satisfaction Healthcare professional satisfaction will be assessed on user experience related to setting up and interpreting the diaries and diary preference.
Healthcare professional satisfaction will be assessed on user experience related to setting up and interpreting the diaries and diary preference.
Through study completion, an average of 1.5 year
See also
  Status Clinical Trial Phase
Recruiting NCT04578899 - "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity" N/A
Active, not recruiting NCT03556891 - Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence N/A
Not yet recruiting NCT05977634 - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder N/A
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Recruiting NCT06201013 - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children N/A
Recruiting NCT03727711 - TPTNS: Home vs Hospital Treatment for Overactive Bladder N/A
Completed NCT00768521 - A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) Phase 1
Completed NCT03625843 - Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing N/A
Completed NCT02211846 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder Phase 1
Completed NCT02857816 - PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB N/A
Completed NCT02835846 - Investigation of the Effect of the Female Urinary Microbiome on Incontinence Phase 4
Completed NCT02202031 - Controlling Urgency Through Relaxation Exercises N/A
Withdrawn NCT02320201 - Foot Neuromodulation for Overactive Bladder in Children N/A
Completed NCT01437670 - Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin N/A
Not yet recruiting NCT01423838 - Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Phase 4
Completed NCT01458197 - A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. Phase 2
Not yet recruiting NCT01409512 - Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder N/A
Withdrawn NCT01210859 - Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents N/A
Terminated NCT01758848 - Physical Therapy for Overactive Bladder N/A
Completed NCT02667470 - Reproducibility Study of OABSS and Its Response to Treatment Phase 4